as on October 29, 2025 at 7:40 pm IST
Day's Low
Day's High
8.18%
Downside
1.91%
Upside
52 Week's Low
52 Week's High
41.87%
Downside
0.05%
Upside
Check United Therapeutics Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$18.8B
EPS (TTM)
26.6517
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.10%
PE Ratio (TTM)
16.2
Industry PE ratio
19.200384615384614
PEG Ratio
1.4347
EBITDA
1.6B
Revenue (TTM)
3.1B
Profit Margin
40.36%
Return On Equity TTM
19.30%
Track how United Therapeutics Corporation P/E has moved over time to understand its valuation trends.
United Therapeutics Corporation in the last 5 years
Lowest (10.67x)
March 31, 2024
Today (16.20x)
October 29, 2025
Industry (19.20x)
October 29, 2025
Highest (19.96x)
September 30, 2021
Today’s Price to Earnings Ratio: 16.20x
Compare market cap, revenue, PE, and other key metrics of United Therapeutics Corporation with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $18.8B | NA | 16.2 | 40.36% | |
| BUY | $41.6B | NA | 20.91 | 13.81% | |
| BUY | $14.6B | 48.99% | 43.6 | 13.88% | |
| BUY | $65.4B | -9.79% | 25.13 | 27.83% |
The United Therapeutics Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
United Therapeutics Corporation investment value today
Current value as on today
₹1,35,240
Returns
₹35,240
(+35.24%)
Returns from United Therapeutics Corporation Stock
₹30,179 (+30.18%)
Dollar Returns*
₹5,061 (+5.06%)
Based on 22 analysts
81.82%
Buy
13.64%
Hold
4.55%
Sell
Based on 22 analysts, 81.82% of analysts recommend a 'BUY' rating for United Therapeutics Corporation. Average target price of $492.85
Get share price movements and forecasts by analysts on United Therapeutics Corporation.
What analysts predicted
6.81%UPSIDE
Target Price
$492.85
Current Price
$459.27
Analyzed by
22 Analysts
Target
$492.85
United Therapeutics Corporation target price $492.85, a slight upside of 6.81% compared to current price of $459.27. According to 22 analysts rating.
Search interest for United Therapeutics Corporation Stock has decreased by -73% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 29 October
Wed, 04:05 PM
-United Therapeutics reports record Q3 2025 revenues of $799.5 million, driven by strong sales of Tyvaso and Orenitram.
Wed, 04:18 PM
-United Therapeutics misses revenue estimates but beats EPS expectations in Q3 2025, stock drops 2.4% post-results.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Best in 3 Years
![]()
In the last 3 years, UTHR has outperformed top 5 stocks with highest market-cap in its industry
Revenue Rich
![]()
Revenue is up for the last 3 quarters, 735.9M → 798.6M (in $), with an average increase of 3.9% per quarter
Price Rise
![]()
In the last 3 months, UTHR stock has moved up by 39.6%
Against Peers
![]()
In the last 1 year, Neurocrine Biosciences Inc. has given 26.8% return, outperforming this stock by 9.1%
Profit Down
![]()
Netprofit is down for the last 2 quarters, 322.2M → 309.5M (in $), with an average decrease of 3.9% per quarter
| Organisation | United Therapeutics Corporation |
| Headquarters | 1000 Spring Street, Silver Spring, MD, United States, 20910 |
| Industry | Health Technology |
| CEO | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation |
Mr. Gil Golden | Senior VP & Chief Medical Officer |
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO |
Mr. Michael I. Benkowitz | President & COO |
Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary |
Harrison Silvers | Manager of Investor Relations |
Kevin T. Gray | Senior Vice President of Strategic Operations & Logistics |
Mr. Patrick Poisson | Executive VP of Technical Operations |
Mr. James C. Edgemond | CFO & Treasurer |
Ms. Holly Hobson | Associate Vice President of Human Resources |
United Therapeutics Corporation share price today is $459.27 as on . United Therapeutics Corporation share today touched a day high of $468.03 and a low of $421.68.
United Therapeutics Corporation share touched a 52 week high of $459.48 on and a 52 week low of $266.98 on . United Therapeutics Corporation stock price today i.e. is trending at $459.27,which is 0.05% down from its 52 week high and 72.02% up from its 52 week low.
United Therapeutics Corporation market capitalisation is $0.02T as on .
Indian investors can start investing in United Therapeutics Corporation (UTHR) shares with as little as ₹88.178 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.78 in United Therapeutics Corporation stock (as per the Rupee-Dollar exchange rate as on ).
Based on United Therapeutics Corporation share’s latest price of $459.27 as on October 29, 2025 at 7:40 pm IST, you will get 0.0218 shares of United Therapeutics Corporation. Learn more about
fractional shares .